Ref: Mumtaz A, Gallagher P, Kirby B, et al. Ann Rheum Dis 2011;70(2):272–7. * HAQ- Health Assessment Questionnaire - see appendix ** DLQI- DERMATOLOGY LIFE QUALITY INDEX - see appendix *** ASQoL- Ankylosing Spondylitis Quality of Life - see appendix Composite psoriatic disease activity index (CPDAI) - includes all domains of PsA (peripheral joints, skin, entheses, dactylitis, and axial disease) score range - 0 to 15. - mainly used in research/clinical trials None (0) Mild (1) Moderate (2) Severe (3) Peripheral ≤4 joints; ≤4 joints but function impaired; >4 joints arthritis normal function 0r >4 joints, normal function and function impaired (TJC/SJC) (HAQ<0.5)* Skin disease PASI ≤10 and PASI ≤10 but DLQI** >10; PASI >10 DLQI** ≤10 or PASI >10 but DLQI** ≤10 and DLQI** >10 ≤3 sites; ≤3 sites but function impaired; >3 sites Enthesitis normal function or >3 sites but normal function and function impaired (HAQ* <0.5) ≤3 digits; ≤3 digits but function impaired; >3 digits Dactylitis normal function or >3 digits but normal function and function impaired (HAQ* <0.5) BASDAI <4; BASDAI >4 but normal function; BASDAI >4 Spinal disease normal function BASDAI <4 but function impaired and function impaired (ASQoL*** <6) Modifed CPDAI - includes domains as in CPDAI, excluding spinal manifestations, scored using a 4-point scale from 0 (no disease activity) to 3 (most severe disease activity), score range of 0–12. - mainly used in research/clinical trials PsA Disease Activity Score (PASDAS) - a complicated composite measure including the following variables: - SJC, TJC, enthesitis (LEI), dactylitis count, physician and patient global assessments, CRP mg/l, SF-36 - provides disease activity states as well as response criteria - used in research/clinical trials Ref: Helliwell PS, FitzGerald O, Fransen J et al. Ann Rheum Dis 2013;72:986–91 Ref: Gladman D. J Rheumatol Suppl 2015;93:14–16. 18
RkJQdWJsaXNoZXIy MjgzNzA=